FDA Approval of Prostate Cancer Imaging Agent a Milestone for Inventor and Johns Hopkins

FDA Approval of Prostate Cancer Imaging Agent a Milestone for Inventor and Johns Hopkins

The U.S. Food and Drug Administration recently approved the first commercially available positron emission tomography (PET) imaging agent targeting the prostate-specific membrane antigen (PSMA). This represents the culmination of 25 years of work for Martin Pomper, M.D., Ph.D., a professor in the Johns Hopkins Medicine Department of Radiology and Radiological Science. Read more about this innovation here.

Recent Posts
Study Shows Patient/Clinician Identity Differences Are Factor in Cancer Care Study Finds Diverse Differences in Microbes in Breast Tumors From Women of Different Races Nutrition Fact, Fiction or Somewhere in Between? ‘Hard To Lose’ Mutations In Tumors May Predict Response To Immunotherapy What are dense breasts? New Blood Test for Cancer The Best Way to Take A Pill, According to Science 8 Ways to Lose Belly Fat and Live a Healthier Life Sunglasses Are More Than Just a Fashion Accessory